Kuopio Health Center
Kuopio, Finland
Location status: Recruiting
Location contact
Pekka Mäntyselkä, Professor
CONTACT
Ulla Mikkonen, MD
CONTACT
NCT Number: NCT05681767
The investigators aim to examine whether a motivational multicomponent lifestyle intervention as a supportive treatment for depression has a beneficial effect on recovery from depression in a primary health care setting.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Kuopio, Finland
Location status: Recruiting
Pekka Mäntyselkä, Professor
CONTACT
Ulla Mikkonen, MD
CONTACT
Depression causes a significant global burden of disease. Among depressed individuals, poor lifestyles, such as physical inactivity, unhealthy diet, and smoking, are common and play a role in the development and maintenance of depression. Robust research evidence recommends applying one-component lifestyle interventions that focus on factors such as a healthy diet or exercise, as a supportive treatment for depression. Currently, however, there is increasing interest in identifying the most effective multicomponent lifestyle intervention that targets more than one unhealthy lifestyle simultaneously in order to reduce depressive symptoms.
The study aims to examine whether a motivational multicomponent lifestyle intervention as a supportive treatment for depression has a beneficial effect on recovery from depression in a primary health care setting. The specific study questions are as follows:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Study intervention and treatment as usual
The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).
The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations.
Treatment as usual
Time frame: Change from baseline at 3, 12 and 24 months
Depressive symptoms
Time frame: Change from baseline at 3, 12 and 24 months
Mental Wellbeing
Time frame: Change from baseline at 3, 12 and 24 months
Health-Related Quality of Life
Time frame: Change from baseline at 3, 12 and 24 months
Stress
Time frame: Change from baseline at 3, 12 and 24 months
Insomnia
Time frame: Change from baseline at 3, 12 and 24 months
Pain
Time frame: Change from baseline at 3, 12 and 24 months
Anxiety
Time frame: Change from baseline at 12 and 24 months
P-Kol, P-KOL-LDL, P-KOL-HDL, P-Trigly
Time frame: Change from baseline at 3, 12 and 24 months
Change in measured weight/BMI
Time frame: Change from baseline at 3, 12 and 24 months
Waist (centimeters)
Time frame: Change from baseline at 3, 12, and 24 months
Blood pressure (diastolic and systolic)
Time frame: Change from baseline at 12 and 24 months
P-Glucose and glycated haemoglobin
Contact information is provided by the study sponsor or research team.
Kuopio University Hospital
Other
Acronym: DEPKuopio
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07033052
Anxiety, Anxiety Disorders
Cleveland, Ohio, United States
View Trial DetailsNCT06713616
Behavior, Behavioral Symptoms
Milford, Connecticut, United States
View Trial DetailsNCT07413874
Addison Disease, Adrenal Gland Diseases
Boone, North Carolina, United States
View Trial DetailsNCT02543983
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial Details